ESR1 and breast carcinoma: Since ERα function is subject to a tiny balance between E3 ubiquitin ligases and deubiquitinases, inhibition of certain deubiquitinases expression or function, which subsequently lead to enhance ERα poly-ubiquitination and degradation, could be an effective strategy for breast cancer treatment [46].